Compounded hormonal pellets: a critical review of current evidence and risks.
作者信息
Wender Maria Celeste Osório, Steiner Marcelo Luis, Fernandes César Eduardo, Damásio Lia Cruz Vaz da Costa, Soares Júnior José Maria, Paiva Lúcia Helena Simões da Costa, Monteiro Ilza Maria Urbano, Quintairos Ricardo de Almeida, Macedo Clayton Luiz Dornelles, Silva Filho Agnaldo Lopes da
机构信息
Universidade Federal do Rio Grande do Sul, Faculty of Medicine, Department of Gynecology and Obstetrics - Porto Alegre (RS), Brazil.
Faculdade de Medicina do ABC, Department of Gynecology - Santo André (SP), Brazil.
出版信息
Rev Assoc Med Bras (1992). 2025 Aug 8;71(7):e20250121. doi: 10.1590/1806-9282.20250121. eCollection 2025.
Abstract
摘要
相似文献
1
Compounded hormonal pellets: a critical review of current evidence and risks.
Rev Assoc Med Bras (1992). 2025 Aug 8;71(7):e20250121. doi: 10.1590/1806-9282.20250121. eCollection 2025.
2
Risk of thromboembolism in patients with COVID-19 who are using hormonal contraception.
Cochrane Database Syst Rev. 2023 Jan 9;1(1):CD014908. doi: 10.1002/14651858.CD014908.pub2.
3
Comparative estrogen exposure from compounded transdermal estradiol creams and Food and Drug Administration-approved transdermal estradiol gels and patches.
Menopause. 2023 Nov 1;30(11):1098-1105. doi: 10.1097/GME.0000000000002266. Epub 2023 Oct 18.
4
Combined hormonal contraceptive use among women with known dyslipidemias: a systematic review of critical safety outcomes.
Contraception. 2016 Sep;94(3):280-7. doi: 10.1016/j.contraception.2015.08.002. Epub 2015 Aug 10.
5
Static and dynamic structural features of single pellets determine the release behaviors of metoprolol succinate sustained-release tablets.
Eur J Pharm Sci. 2020 Apr 18;149:105324. doi: 10.1016/j.ejps.2020.105324.
6
Combining in vivo and in vitro approaches to investigate the effect of sainfoin on strongyle infection, immunity, and large intestine ecosystem of horses.
J Anim Sci. 2025 Jan 4;103. doi: 10.1093/jas/skaf100.
7
Animal models of hormonal contraceptives: Understanding drug-specific and user-specific variables.
J Neuroendocrinol. 2025 Jul;37(7):e13500. doi: 10.1111/jne.13500. Epub 2025 Feb 10.
8
Treatments for seizures in catamenial (menstrual-related) epilepsy.
Cochrane Database Syst Rev. 2021 Sep 16;9(9):CD013225. doi: 10.1002/14651858.CD013225.pub3.
9
Reasons for rejecting hormonal contraception in Western countries: A systematic review.
Soc Sci Med. 2021 Sep;284:114247. doi: 10.1016/j.socscimed.2021.114247. Epub 2021 Jul 20.
10
Systemic hormonal contraception initiation after abortion: A systematic review and meta-analysis.
Contraception. 2021 May;103(5):291-304. doi: 10.1016/j.contraception.2021.01.017. Epub 2021 Feb 3.
本文引用的文献
1
Concerns about safety and efficacy of compounded bioidentical hormone therapy.
Menopause. 2021 Jun 14;28(8):847-849. doi: 10.1097/GME.0000000000001813.
2
Low complication rates of testosterone and estradiol implants for androgen and estrogen replacement therapy in over 1 million procedures.
Ther Adv Endocrinol Metab. 2021 May 27;12:20420188211015238. doi: 10.1177/20420188211015238. eCollection 2021.
3
Evaluation of the Quality of Perinatal Trials: Making the GRADE.
Neonatology. 2021;118(3):378-383. doi: 10.1159/000516239. Epub 2021 May 4.
4
Compounded bioidentical hormone therapy: new recommendations from the 2020 National Academies of Sciences, Engineering, and Medicine.
Menopause. 2021 Mar 11;28(5):576-578. doi: 10.1097/GME.0000000000001735.
5
Incidence of invasive breast cancer in women treated with testosterone implants: a prospective 10-year cohort study.
BMC Cancer. 2019 Dec 30;19(1):1271. doi: 10.1186/s12885-019-6457-8.
6
Global Consensus Position Statement on the Use of Testosterone Therapy for Women.
Climacteric. 2019 Oct;22(5):429-434. doi: 10.1080/13697137.2019.1637079. Epub 2019 Sep 2.
7
Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data.
Lancet Diabetes Endocrinol. 2019 Oct;7(10):754-766. doi: 10.1016/S2213-8587(19)30189-5. Epub 2019 Jul 25.
8
Use of the etonogestrel implant and levonorgestrel intrauterine device beyond the U.S. Food and Drug Administration-approved duration.
Obstet Gynecol. 2015 Mar;125(3):599-604. doi: 10.1097/AOG.0000000000000690.
9
Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study.
Maturitas. 2013 Dec;76(4):342-9. doi: 10.1016/j.maturitas.2013.08.002. Epub 2013 Sep 10.
10
Testosterone implants in women: pharmacological dosing for a physiologic effect.
Maturitas. 2013 Feb;74(2):179-84. doi: 10.1016/j.maturitas.2012.11.004. Epub 2012 Dec 21.
Zotero 插件